
    
      On March 24, 2009, Pfizer Inc. stopped late stage Geodon pediatric clinical trials in
      schizophrenia (A1281134 - placebo controlled; A1281135 - open label). As recommended by the
      DSMB, these studies were stopped due to lack of efficacy. No safety concerns were identified.
    
  